Europharm SMC International Business Meeting 2027
Join us for the Europharm International Business Meeting 2027 in Prague!
Are you ready to expand your network and seize new business opportunities?
Join Europharm SMC in Prague for two days of insightful lectures, strategic B2B meetings and unparalleled networking with leading SMEs in the pharmaceutical sector.
Why should you attend?
Europharm SMC is the recognised voice of European pharmaceutical SMEs, actively engaging with the European Commission and EMA to ensure your interests are heard.
More than 80 decision-makers from across Europe will gather in Prague – don’t miss the chance to be part of this influential community.
The Very Early Bird Rate is only available until 24th November 2026 – with limited seats at this price.
Your registration includes access to expert-led insightful lectures, exclusive B2B meetings and our prestigious Gala Dinner.
Meetings
Explore Europharm meetings and webinars.
Explore meetings →Speakers and delegates
Discover the programme and speakers for this event.
View programme and speakers →Member follow-up
Contact Europharm for help preparing your participation and following up after the meeting.
Contact Europharm →Programme overview
This presentation provides a data-driven perspective on pharmaceutical markets in Central and Eastern Europe, covering key developments across the Rx and OTC segments and overall market performance. It includes benchmarking of mid-sized pharmaceutical companies against large market players and highlights key success factors, growth opportunities, and innovation trends relevant to pharmaceutical SMEs.
Presented at the Europharm SMC Annual Meeting in Prague, the session will offer insights to help participants better understand regional market dynamics and identify opportunities for business development and cross-border collaboration.
The insights are based on analyses by IQVIA, a leading global provider of healthcare data, analytics, and technology solutions, supporting stakeholders across the life sciences and healthcare ecosystem.
This session will provide the latests updates and an overview of the evolving EU legislative framework and its implications for small and medium-sized pharmaceutical enterprises. It will highlight key regulatory changes, upcoming requirements, and their practical impact on SME development, compliance, and market access. Particular attention will be given to challenges and opportunities for innovation. The presentation will also outline how SMEs can anticipate and prepare for these changes. Finally, it will emphasise the importance of dialogue and support mechanisms at EMA.
Regulatory Inspections are not a Company audit, they are not for your benefit, but the Regulators, ensuring you already have compliant systems to protect patients from all medicines, generic or otherwise.
This presentation looks at the preparation, findings from the EMA for 2025 and the cost of having an Inspection – with and without findings.
Also, there will be coverage of the new PV Module changes and their impact on processes and Regulatory expectations.
Tecnifar is looking to build partnerships that bring innovative healthcare solutions to patients. This presentation will outline our licensing-in interests and licensing-out opportunities, alongside our openness to co-development collaborations. By combining complementary expertise and capabilities, we aim to advance promising projects and create shared value with our partners.
Meet Eminvest through the stories a standard company presentation tends to leave out.
Three friends, one plan: build a company, grow it, sell it - and start again. Then do it again. New categories, new products, the right people, the right investments - and happy customers along the way.
So, what’s their secret?”
Every pharma company has molecules with untapped potential: new indications, new formulations, new patient populations.
What if you could unlock them without starting from zero?
At VECTORB2B, we guide products through their next evolution, from repurposing strategy, toxicology and proof of concept to clinical trials and real-world evidence, backed by a network of scientific, preclinical and clinical expertise.
In 10 minutes, we’ll show how this end-to-end approach turns existing assets into new opportunities, and the partnerships we’re looking for.
Ten minutes that may change how you look at your portfolio.
Speakers and contributors
Opening Speech
The Pharmaceutical Industry Drives Innovation: Central and Eastern European Market Trends 2026 and Beyond
This presentation provides a data-driven perspective on pharmaceutical markets in Central and Eastern Europe, covering key developments across the Rx and OTC segments and overall market performance. It includes benchmarking of mid-sized pharmaceutical companies against large market players and highlights key success factors, growth opportunities, and innovation trends relevant to pharmaceutical SMEs.
Presented at the Europharm SMC Annual Meeting in Prague, the session will offer insights to help participants better understand regional market dynamics and identify opportunities for business development and cross-border collaboration.
The insights are based on analyses by IQVIA, a leading global provider of healthcare data, analytics, and technology solutions, supporting stakeholders across the life sciences and healthcare ecosystem.
Latest Update on the Legislative Framework and Its Impact on SMEs
This session will provide the latests updates and an overview of the evolving EU legislative framework and its implications for small and medium-sized pharmaceutical enterprises. It will highlight key regulatory changes, upcoming requirements, and their practical impact on SME development, compliance, and market access. Particular attention will be given to challenges and opportunities for innovation. The presentation will also outline how SMEs can anticipate and prepare for these changes. Finally, it will emphasise the importance of dialogue and support mechanisms at EMA.
AI in Pharma: a transformative Pilot in Market Access
Representative demo presentation by Henri Jonckheere.
Regulatory Authority PV Inspections – What are they looking at and are you Ready?
Regulatory Inspections are not a Company audit, they are not for your benefit, but the Regulators, ensuring you already have compliant systems to protect patients from all medicines, generic or otherwise.
This presentation looks at the preparation, findings from the EMA for 2025 and the cost of having an Inspection – with and without findings.
Also, there will be coverage of the new PV Module changes and their impact on processes and Regulatory expectations.
Tecnifar: Partnering for What’s Next
Tecnifar is looking to build partnerships that bring innovative healthcare solutions to patients. This presentation will outline our licensing-in interests and licensing-out opportunities, alongside our openness to co-development collaborations. By combining complementary expertise and capabilities, we aim to advance promising projects and create shared value with our partners.
Tecnifar: Partnering for What’s Next
Not another “What we do” presentation. Promise
Meet Eminvest through the stories a standard company presentation tends to leave out.
Three friends, one plan: build a company, grow it, sell it - and start again. Then do it again. New categories, new products, the right people, the right investments - and happy customers along the way.
So, what’s their secret?”
Your Best Next Product May Already Be in Your Portfolio
Every pharma company has molecules with untapped potential: new indications, new formulations, new patient populations.
What if you could unlock them without starting from zero?
At VECTORB2B, we guide products through their next evolution, from repurposing strategy, toxicology and proof of concept to clinical trials and real-world evidence, backed by a network of scientific, preclinical and clinical expertise.
In 10 minutes, we’ll show how this end-to-end approach turns existing assets into new opportunities, and the partnerships we’re looking for.
Ten minutes that may change how you look at your portfolio.